# A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

> **NCT06041061** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sinocelltech Ltd.** · enrollment: 18000 (actual)

## Conditions studied

- HPV InfectioN
- HPV-Related Carcinoma

## Interventions

- **BIOLOGICAL:** Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT06041061
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-13
- **Primary completion:** 2024-03
- **Final completion:** 2028-08
- **Target enrollment:** 18000 (ACTUAL)
- **Last updated:** 2023-09-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041061, "A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06041061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*